Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Fig. 4

The Forrest plot for AE ≥ Grade 3 for patients with HR+/HER2- advanced breast cancer after progression on ≥ 1 line of ET. Note: AE, adverse event; progression-free survival; CI, confidence interval; HR, hazard ratio; HR+/HER2-, hormone receptor-positive and human epidermal growth factor receptor 2-negative; SERDs, selective estrogen receptor degrader

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us